دورية أكاديمية
أعرض في EDS

First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.

التفاصيل البيبلوغرافية
العنوان: First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
المؤلفون: Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U900 Research Unit, Saint-Cloud, France.; Faculty of Medicine, Paris-Saclay University, Paris, France., Ghiani M; Department of Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy., Cau MC; Department of Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy., Depenni R; Department of Oncology and Hematology, Università degli Studi di Modena e Reggio Emilia, Modena, Italy., Ronzino G; Oncology Unit, Ospedale, Vito Fazzi, Lecce, Italy., Bonomo P; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Montesarchio V; AORN dei Colli, Monaldi Hospital, Naples, Italy., Leo L; AORN dei Colli, Monaldi Hospital, Naples, Italy., Schulten J; Global Medical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany., Salmio S; Global Medical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany., Messinger D; Statistics, Prometris GmbH, Mannheim, Germany., Sbrana A; Service of Pneumo-Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.; Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy., Borcoman E; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France., Ghi MG; Oncology Unit 2, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
المصدر: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2023 May; Vol. 6 (5), pp. e1804. Date of Electronic Publication: 2023 Apr 17.
نوع المنشور: Observational Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101747728 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2573-8348 (Electronic) Linking ISSN: 25738348 NLM ISO Abbreviation: Cancer Rep (Hoboken) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hoboken, NJ : John Wiley & Sons, Inc., [2018]-
مواضيع طبية MeSH: Platinum*/therapeutic use , Head and Neck Neoplasms*/drug therapy, Humans ; Cetuximab/adverse effects ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Carboplatin ; Prospective Studies ; Neoplasm Recurrence, Local/pathology ; Fluorouracil ; Cisplatin
مستخلص: Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Aims: This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes.
Methods and Results: Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related.
Conclusion: In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial.
Clinical Trial Registration Number: EMR 062202-566.
(© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
References: Lancet Oncol. 2021 Jun;22(6):883-892. (PMID: 33989559)
N Engl J Med. 2020 Jan 2;382(1):60-72. (PMID: 31893516)
Mayo Clin Proc. 2008 Apr;83(4):489-501. (PMID: 18380996)
N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101)
Ann Oncol. 2014 Apr;25(4):801-807. (PMID: 24577117)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
Front Oncol. 2017 May 09;7:72. (PMID: 28536670)
Int J Mol Sci. 2019 Mar 26;20(6):. (PMID: 30917608)
Lancet Oncol. 2021 Apr;22(4):463-475. (PMID: 33684370)
Front Oncol. 2016 Aug 31;6:199. (PMID: 27630826)
Front Oncol. 2019 May 20;9:383. (PMID: 31165040)
Lancet Oncol. 2021 Jun;22(6):e228-e229. (PMID: 34087138)
Cancer Rep (Hoboken). 2023 May;6(5):e1804. (PMID: 37069784)
فهرسة مساهمة: Keywords: cetuximab; combination chemotherapy; first-line; observational study; squamous cell carcinoma of head and neck
المشرفين على المادة: PQX0D8J21J (Cetuximab)
49DFR088MY (Platinum)
BG3F62OND5 (Carboplatin)
U3P01618RT (Fluorouracil)
Q20Q21Q62J (Cisplatin)
تواريخ الأحداث: Date Created: 20230418 Date Completed: 20230512 Latest Revision: 20230515
رمز التحديث: 20230516
مُعرف محوري في PubMed: PMC10172179
DOI: 10.1002/cnr2.1804
PMID: 37069784
قاعدة البيانات: MEDLINE
الوصف
تدمد:2573-8348
DOI:10.1002/cnr2.1804